JPS6236487B2 - - Google Patents
Info
- Publication number
- JPS6236487B2 JPS6236487B2 JP55070632A JP7063280A JPS6236487B2 JP S6236487 B2 JPS6236487 B2 JP S6236487B2 JP 55070632 A JP55070632 A JP 55070632A JP 7063280 A JP7063280 A JP 7063280A JP S6236487 B2 JPS6236487 B2 JP S6236487B2
- Authority
- JP
- Japan
- Prior art keywords
- factor
- ammonium sulfate
- aqueous solution
- fractionation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 17
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 17
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000005194 fractionation Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000000356 contaminant Substances 0.000 claims description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 229940019700 blood coagulation factors Drugs 0.000 claims description 2
- 239000012503 blood component Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 9
- 102000009123 Fibrin Human genes 0.000 description 8
- 108010073385 Fibrin Proteins 0.000 description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102000006395 Globulins Human genes 0.000 description 7
- 108010044091 Globulins Proteins 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000014763 coagulation protein disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7063280A JPS56166121A (en) | 1980-05-27 | 1980-05-27 | Purifying method of human blood coagulation factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7063280A JPS56166121A (en) | 1980-05-27 | 1980-05-27 | Purifying method of human blood coagulation factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56166121A JPS56166121A (en) | 1981-12-21 |
| JPS6236487B2 true JPS6236487B2 (fr) | 1987-08-07 |
Family
ID=13437201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7063280A Granted JPS56166121A (en) | 1980-05-27 | 1980-05-27 | Purifying method of human blood coagulation factor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56166121A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58121219A (ja) * | 1982-01-11 | 1983-07-19 | Green Cross Corp:The | ヒト血液凝固第１０３因子の製造方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5842623B2 (ja) * | 1976-08-09 | 1983-09-21 | 株式会社東芝 | ハイブリツドｉｃ |
-
1980
- 1980-05-27 JP JP7063280A patent/JPS56166121A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56166121A (en) | 1981-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4297344A (en) | Blood coagulation factors and process for their manufacture | |
| CA1074698A (fr) | Methode pour augmenter la production de facteur antihemophilique viii dans le sang et le plasma | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| US3956259A (en) | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate | |
| US5177194A (en) | Process for purifying immune serum globulins | |
| US4341764A (en) | Method of preparing fibronectin and antihemophilic factor | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| PL168353B1 (pl) | Sposób wytwarzania zatezonego, standaryzowanego ludzkiego c z y n n i k a von Willebranda o wysokiej czystosci PL PL PL PL PL PL PL | |
| US4087415A (en) | Antithrombin III | |
| US4404131A (en) | Method of producing a factor-VIII(AHF)-high-concentrate | |
| JPS6187626A (ja) | 高純度抗血友病性因子濃縮物の製造法 | |
| JPS6160614A (ja) | 第８因子製剤およびその製造方法 | |
| EP0148843B1 (fr) | Concentre du facteur antihemophilique viii et son procede de production | |
| USH1509H (en) | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate | |
| JPH0348888B2 (fr) | ||
| US4348315A (en) | Process in purification and concentration of the factor VIII-complex | |
| CA1046406A (fr) | Compose du genre plasminogene et methode d'extraction de tels composes a partir de la pulpe placentaire | |
| JP2003518513A (ja) | 血漿プロテアーゼからのフィブリノゲンの分離 | |
| US4455300A (en) | Fibronectin compositions | |
| EA006209B1 (ru) | ПРЕПАРАТ, СОДЕРЖАЩИЙ ГЕМОСТАТИЧЕСКИ АКТИВНЫЙ ФАКТОР vWF, И СПОСОБ ЕГО ПОЛУЧЕНИЯ | |
| US4285933A (en) | Process for concentrating blood coagulation Factor XIII derived from human placentae | |
| US4025500A (en) | Preparation of albumin by fractionation of blood plasma or serum | |
| US4177262A (en) | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots | |
| EP0052874A1 (fr) | Méthode de génération de l'activité procoagulante du facteur VIII | |
| US4406886A (en) | Purification of antihemophilia factor VIII by precipitation with zinc ions |